Literature DB >> 10584458

Investigation of an opioid response categorization in advanced cancer patients.

S Mercadante1, F Fulfaro, A Casuccio, L Barresi.   

Abstract

The aim of this study was to investigate a possible distinction in three categories of opioid response and to identify possible factors associated with a poor response. A prospective survey was carried out in 105 consecutive patients requiring morphine for at least 4 weeks before death. Mean pain intensity, opioid doses and symptom intensity at weekly intervals, pain syndromes, and the presence of psychological distress were assessed. Opioid escalation index (OEI%) was calculated from the parameters recorded. Three categories were considered, including (1) patients with slow increments of opioid dose and a mean analgesic 10-cm visual analogue scale (VAS) less than 4 (responders), (2) patients with an OEI% more than 5 but a mean VAS less than 4 (partial responders), and (3) patients with a mean VAS more than 4 (poor responders). Treating physicians were asked to make a judgment on the pain treatment difficulties on a numerical scale (0-10). Significant differences in opioid starting dose (OSD), opioid dose at--4 weeks, nausea and vomiting at--1 week, opioid maximum doses, mean VAS, and OEI were found in the three categories of response. Significant correlations with the physician judgment were found for opioid maximum dose, mean VAS, VAS at the different time intervals, the doses used at the different intervals, OEI, and confusion. Neuropathic pain was significantly associated with a judgment of poor pain outcome. The correlation between the physician judgment and the categories of opioid response was highly significant. Seven of the 12 patients in the third category (poor response) were considered as having a relevant psychological distress. The categorization of the opioid response used in this study could be used in clinical research and as an audit tool, and could be tested in other settings to compare different treatments.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10584458     DOI: 10.1016/s0885-3924(99)00099-8

Source DB:  PubMed          Journal:  J Pain Symptom Manage        ISSN: 0885-3924            Impact factor:   3.612


  11 in total

1.  Impact of cachexia on pharmacokinetic disposition of and clinical responses to oxycodone in cancer patients.

Authors:  Takafumi Naito; Masaki Tashiro; Keisuke Yamamoto; Kazunori Ohnishi; Yoshiyuki Kagawa; Junichi Kawakami
Journal:  Eur J Clin Pharmacol       Date:  2012-03-23       Impact factor: 2.953

2.  The effects of alcoholism and smoking on advanced cancer patients admitted to an acute supportive/palliative care unit.

Authors:  Sebastiano Mercadante; Claudio Adile; Patrizia Ferrera; Alessandra Casuccio
Journal:  Support Care Cancer       Date:  2017-02-16       Impact factor: 3.603

3.  Palliative sedation at the end of life at a tertiary cancer center.

Authors:  Augusto Caraceni; Ernesto Zecca; Cinzia Martini; Giovanna Gorni; Tiziana Campa; Cinzia Brunelli; Franco De Conno
Journal:  Support Care Cancer       Date:  2011-07-16       Impact factor: 3.603

4.  Assessing the response to opioids in cancer patients: a methodological proposal and the results.

Authors:  O Corli; A Roberto; M T Greco; M Montanari
Journal:  Support Care Cancer       Date:  2014-12-05       Impact factor: 3.603

5.  Addition of a second opioid may improve opioid response in cancer pain: preliminary data.

Authors:  Sebastiano Mercadante; Patrizia Villari; Patrizia Ferrera; Alessandra Casuccio
Journal:  Support Care Cancer       Date:  2004-11       Impact factor: 3.603

6.  Opioid use and effectiveness of its prescription at discharge in an acute pain relief and palliative care unit.

Authors:  Sebastiano Mercadante; Giovanna Prestia; Maurizio Ranieri; Antonello Giarratano; Alessandra Casuccio
Journal:  Support Care Cancer       Date:  2013-02-12       Impact factor: 3.603

7.  Prevalence of delirium in advanced cancer patients in home care and hospice and outcomes after 1 week of palliative care.

Authors:  Sebastiano Mercadante; Francesco Masedu; Isabella Balzani; Daniela De Giovanni; Luigi Montanari; Cristina Pittureri; Raffaella Bertè; Domenico Russo; Laura Ursini; Franco Marinangeli; Federica Aielli
Journal:  Support Care Cancer       Date:  2017-10-05       Impact factor: 3.603

Review 8.  A "TNM" classification system for cancer pain: the Edmonton Classification System for Cancer Pain (ECS-CP).

Authors:  Robin L Fainsinger; Cheryl L Nekolaichuk
Journal:  Support Care Cancer       Date:  2008-03-04       Impact factor: 3.603

9.  A comparison between the administration of oral prolonged-release oxycodone-naloxone and transdermal fentanyl in patients with moderate-to-severe cancer pain: a propensity score analysis.

Authors:  A Roberto; M T Greco; L Legramandi; F Galli; M Galli; O Corli
Journal:  J Pain Res       Date:  2017-09-04       Impact factor: 3.133

10.  Efficacy and tolerability of oral oxycodone and oxycodone/naloxone combination in opioid-naïve cancer patients: a propensity analysis.

Authors:  Marzia Lazzari; Maria Teresa Greco; Claudio Marcassa; Simona Finocchi; Clarissa Caldarulo; Oscar Corli
Journal:  Drug Des Devel Ther       Date:  2015-11-02       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.